{"title":"内镜超声引导下胰腺积液治疗的并发症负担和疗效：基于全国数据验证的多中心研究。","authors":"Tsuyoshi Hamada, Atsuhiro Masuda, Nobuaki Michihata, Tomotaka Saito, Masahiro Tsujimae, Mamoru Takenaka, Shunsuke Omoto, Takuji Iwashita, Shinya Uemura, Shogo Ota, Hideyuki Shiomi, Toshio Fujisawa, Sho Takahashi, Saburo Matsubara, Kentaro Suda, Hiroki Matsui, Akinori Maruta, Kensaku Yoshida, Keisuke Iwata, Mitsuru Okuno, Nobuhiko Hayashi, Tsuyoshi Mukai, Kiyohide Fushimi, Ichiro Yasuda, Hiroyuki Isayama, Hideo Yasunaga, Yousuke Nakai","doi":"10.1111/den.14924","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The appropriate holistic management is mandatory for successful endoscopic ultrasound (EUS)-guided treatment of pancreatic fluid collections (PFCs). However, comorbidity status has not been fully examined in relation to clinical outcomes of this treatment.</p><p><strong>Methods: </strong>Using a multi-institutional cohort of 406 patients receiving EUS-guided treatment of PFCs in 2010-2020, we examined the associations of Charlson Comorbidity Index (CCI) with in-hospital mortality and other clinical outcomes. Multivariable logistic regression analysis was conducted with adjustment for potential confounders. The findings were validated using a Japanese nationwide inpatient database including 4053 patients treated at 486 hospitals in 2010-2020.</p><p><strong>Results: </strong>In the clinical multi-institutional cohort, CCI was positively associated with the risk of in-hospital mortality (P<sub>trend</sub> < 0.001). Compared to patients with CCI = 0, patients with CCI of 1-2, 3-5, and ≥6 had adjusted odds ratios (95% confidence intervals) of 0.76 (0.22-2.54), 5.39 (1.74-16.7), and 8.77 (2.36-32.6), respectively. In the nationwide validation cohort, a similar positive association was observed; the corresponding odds ratios (95% confidence interval) were 1.21 (0.90-1.64), 1.52 (0.92-2.49), and 4.84 (2.63-8.88), respectively (P<sub>trend</sub> < 0.001). The association of higher CCI with longer length of stay was observed in the nationwide cohort (P<sub>trend</sub> < 0.001), but not in the clinical cohort (P<sub>trend</sub> = 0.18). CCI was not associated with the risk of procedure-related adverse events.</p><p><strong>Conclusions: </strong>Higher levels of CCI were associated with a higher risk of in-hospital mortality among patients receiving EUS-guided treatment of PFCs, suggesting the potential of CCI in stratifying the periprocedural mortality risk.</p><p><strong>Trial registration: </strong>The research based on the clinical data from the WONDERFULcohort was registered with UMIN-CTR (registration number UMIN000044130).</p>","PeriodicalId":72813,"journal":{"name":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comorbidity burden and outcomes of endoscopic ultrasound-guided treatment of pancreatic fluid collections: Multicenter study with nationwide data-based validation.\",\"authors\":\"Tsuyoshi Hamada, Atsuhiro Masuda, Nobuaki Michihata, Tomotaka Saito, Masahiro Tsujimae, Mamoru Takenaka, Shunsuke Omoto, Takuji Iwashita, Shinya Uemura, Shogo Ota, Hideyuki Shiomi, Toshio Fujisawa, Sho Takahashi, Saburo Matsubara, Kentaro Suda, Hiroki Matsui, Akinori Maruta, Kensaku Yoshida, Keisuke Iwata, Mitsuru Okuno, Nobuhiko Hayashi, Tsuyoshi Mukai, Kiyohide Fushimi, Ichiro Yasuda, Hiroyuki Isayama, Hideo Yasunaga, Yousuke Nakai\",\"doi\":\"10.1111/den.14924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The appropriate holistic management is mandatory for successful endoscopic ultrasound (EUS)-guided treatment of pancreatic fluid collections (PFCs). However, comorbidity status has not been fully examined in relation to clinical outcomes of this treatment.</p><p><strong>Methods: </strong>Using a multi-institutional cohort of 406 patients receiving EUS-guided treatment of PFCs in 2010-2020, we examined the associations of Charlson Comorbidity Index (CCI) with in-hospital mortality and other clinical outcomes. Multivariable logistic regression analysis was conducted with adjustment for potential confounders. The findings were validated using a Japanese nationwide inpatient database including 4053 patients treated at 486 hospitals in 2010-2020.</p><p><strong>Results: </strong>In the clinical multi-institutional cohort, CCI was positively associated with the risk of in-hospital mortality (P<sub>trend</sub> < 0.001). Compared to patients with CCI = 0, patients with CCI of 1-2, 3-5, and ≥6 had adjusted odds ratios (95% confidence intervals) of 0.76 (0.22-2.54), 5.39 (1.74-16.7), and 8.77 (2.36-32.6), respectively. In the nationwide validation cohort, a similar positive association was observed; the corresponding odds ratios (95% confidence interval) were 1.21 (0.90-1.64), 1.52 (0.92-2.49), and 4.84 (2.63-8.88), respectively (P<sub>trend</sub> < 0.001). The association of higher CCI with longer length of stay was observed in the nationwide cohort (P<sub>trend</sub> < 0.001), but not in the clinical cohort (P<sub>trend</sub> = 0.18). CCI was not associated with the risk of procedure-related adverse events.</p><p><strong>Conclusions: </strong>Higher levels of CCI were associated with a higher risk of in-hospital mortality among patients receiving EUS-guided treatment of PFCs, suggesting the potential of CCI in stratifying the periprocedural mortality risk.</p><p><strong>Trial registration: </strong>The research based on the clinical data from the WONDERFULcohort was registered with UMIN-CTR (registration number UMIN000044130).</p>\",\"PeriodicalId\":72813,\"journal\":{\"name\":\"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/den.14924\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/den.14924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comorbidity burden and outcomes of endoscopic ultrasound-guided treatment of pancreatic fluid collections: Multicenter study with nationwide data-based validation.
Objectives: The appropriate holistic management is mandatory for successful endoscopic ultrasound (EUS)-guided treatment of pancreatic fluid collections (PFCs). However, comorbidity status has not been fully examined in relation to clinical outcomes of this treatment.
Methods: Using a multi-institutional cohort of 406 patients receiving EUS-guided treatment of PFCs in 2010-2020, we examined the associations of Charlson Comorbidity Index (CCI) with in-hospital mortality and other clinical outcomes. Multivariable logistic regression analysis was conducted with adjustment for potential confounders. The findings were validated using a Japanese nationwide inpatient database including 4053 patients treated at 486 hospitals in 2010-2020.
Results: In the clinical multi-institutional cohort, CCI was positively associated with the risk of in-hospital mortality (Ptrend < 0.001). Compared to patients with CCI = 0, patients with CCI of 1-2, 3-5, and ≥6 had adjusted odds ratios (95% confidence intervals) of 0.76 (0.22-2.54), 5.39 (1.74-16.7), and 8.77 (2.36-32.6), respectively. In the nationwide validation cohort, a similar positive association was observed; the corresponding odds ratios (95% confidence interval) were 1.21 (0.90-1.64), 1.52 (0.92-2.49), and 4.84 (2.63-8.88), respectively (Ptrend < 0.001). The association of higher CCI with longer length of stay was observed in the nationwide cohort (Ptrend < 0.001), but not in the clinical cohort (Ptrend = 0.18). CCI was not associated with the risk of procedure-related adverse events.
Conclusions: Higher levels of CCI were associated with a higher risk of in-hospital mortality among patients receiving EUS-guided treatment of PFCs, suggesting the potential of CCI in stratifying the periprocedural mortality risk.
Trial registration: The research based on the clinical data from the WONDERFULcohort was registered with UMIN-CTR (registration number UMIN000044130).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
